125 related articles for article (PubMed ID: 9701731)
1. Increased transforming growth factor beta1 plasma level in patients with renal cell carcinoma: a tumor-specific marker?
Wunderlich H; Steiner T; Kosmehl H; Junker U; Reinhold D; Reichelt O; Zermann DH; Schubert J
Urol Int; 1998 Aug; 60(4):205-7. PubMed ID: 9701731
[TBL] [Abstract][Full Text] [Related]
2. TGF-beta1 in patients with renal cell carcinoma.
Hegele A; Varga Z; von Knobloch R; Heidenreich A; Kropf J; Hofmann R
Urol Res; 2002 May; 30(2):126-9. PubMed ID: 12086018
[TBL] [Abstract][Full Text] [Related]
3. Serum transforming growth factor-beta1 in patients with renal cell carcinoma.
Wunderlich H; Steiner T; Junker U; Knöfel B; Schlichter A; Schubert J
J Urol; 1997 May; 157(5):1602-3. PubMed ID: 9112485
[TBL] [Abstract][Full Text] [Related]
4. Elevated plasma TGF-beta1 in renal diseases: cause or consequence?
Junker U; Haufe CC; Nuske K; Rebstock K; Steiner T; Wunderlich H; Junker K; Reinhold D
Cytokine; 2000 Jul; 12(7):1084-91. PubMed ID: 10880255
[TBL] [Abstract][Full Text] [Related]
5. Transforming growth factor beta 1 is significantly elevated in plasma of patients suffering from renal cell carcinoma.
Junker U; Knoefel B; Nuske K; Rebstock K; Steiner T; Wunderlich H; Junker K; Reinhold D
Cytokine; 1996 Oct; 8(10):794-8. PubMed ID: 8980881
[TBL] [Abstract][Full Text] [Related]
6. High YKL-40 is associated with poor survival in patients with renal cell carcinoma: a novel independent prognostic marker.
Väänänen T; Kallio J; Vuolteenaho K; Ojala A; Luukkaala T; Hämäläinen M; Tammela T; Kellokumpu-Lehtinen PL; Moilanen E
Scand J Urol; 2017 Oct; 51(5):367-372. PubMed ID: 28644702
[TBL] [Abstract][Full Text] [Related]
7. Regulatory T cells and TGF-β1 in clinically localized renal cell carcinoma: Comparison with age-matched healthy controls.
Kim CS; Kim Y; Kwon T; Yoon JH; Kim KH; You D; Hong JH; Ahn H; Jeong IG
Urol Oncol; 2015 Mar; 33(3):113.e19-25. PubMed ID: 25499257
[TBL] [Abstract][Full Text] [Related]
8. Elevated serum levels of transforming growth factor-beta1 in patients with colorectal carcinoma: its association with tumor progression and its significant decrease after curative surgical resection.
Shim KS; Kim KH; Han WS; Park EB
Cancer; 1999 Feb; 85(3):554-61. PubMed ID: 10091729
[TBL] [Abstract][Full Text] [Related]
9. Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma.
Gayed BA; Gillen J; Christie A; Peña-Llopis S; Xie XJ; Yan J; Karam JA; Raj G; Sagalowsky AI; Lotan Y; Margulis V; Brugarolas J
BMC Urol; 2015 Apr; 15():24. PubMed ID: 25885592
[TBL] [Abstract][Full Text] [Related]
10. Prolyl hydroxylase-3 is a novel renal cell carcinoma biomarker.
Kim KH; Lee HH; Yoon YE; Na JC; Kim KS; Han WK
Investig Clin Urol; 2019 Nov; 60(6):425-431. PubMed ID: 31692952
[TBL] [Abstract][Full Text] [Related]
11. TGF-beta promotes the establishment of renal cell carcinoma bone metastasis.
Kominsky SL; Doucet M; Brady K; Weber KL
J Bone Miner Res; 2007 Jan; 22(1):37-44. PubMed ID: 17032147
[TBL] [Abstract][Full Text] [Related]
12. Involvement of transforming growth factor beta 1 in the transcriptional regulation of nicotinamide N-methyltransferase in clear cell renal cell carcinoma.
Campagna R; Cecati M; Pozzi V; Fumarola S; Pompei V; Milanese G; Galosi AB; Sartini D; Emanuelli M
Cell Mol Biol (Noisy-le-grand); 2018 May; 64(7):51-55. PubMed ID: 29974846
[TBL] [Abstract][Full Text] [Related]
13. Plasma levels and hepatic mRNA expression of transforming growth factor-beta1 in patients with fulminant hepatic failure.
Miwa Y; Harrison PM; Farzaneh F; Langley PG; Williams R; Hughes RD
J Hepatol; 1997 Nov; 27(5):780-8. PubMed ID: 9382963
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of peri-operative peripheral and renal venous levels of pro- and anti-angiogenic factors and their relevance in patients with renal cell carcinoma.
Klatte T; Böhm M; Nelius T; Filleur S; Reiher F; Allhoff EP
BJU Int; 2007 Jul; 100(1):209-14. PubMed ID: 17428240
[TBL] [Abstract][Full Text] [Related]
15. Plasma thymosin-α1 level as a potential biomarker in urothelial and renal cell carcinoma.
Jou YC; Tsai YS; Hsieh HY; Chen SY; Tsai HT; Chen KJ; Wang ST; Shiau AL; Wu CL; Tzai TS
Urol Oncol; 2013 Nov; 31(8):1806-11. PubMed ID: 22609059
[TBL] [Abstract][Full Text] [Related]
16. Significance of transforming growth factor beta1 as a new tumor marker for colorectal cancer.
Narai S; Watanabe M; Hasegawa H; Nishibori H; Endo T; Kubota T; Kitajima M
Int J Cancer; 2002 Feb; 97(4):508-11. PubMed ID: 11802214
[TBL] [Abstract][Full Text] [Related]
17. Significance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung cancer.
De Jaeger K; Seppenwoolde Y; Kampinga HH; Boersma LJ; Belderbos JS; Lebesque JV
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1378-87. PubMed ID: 15050313
[TBL] [Abstract][Full Text] [Related]
18. Elevated plasma levels of transforming growth factor-beta 1 (TGF-beta 1) in patients with advanced breast cancer: association with disease progression.
Ivanović V; Todorović-Raković N; Demajo M; Nesković-Konstantinović Z; Subota V; Ivanisević-Milovanović O; Nikolić-Vukosavljević D
Eur J Cancer; 2003 Mar; 39(4):454-61. PubMed ID: 12751375
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of transforming growth factor beta1 are significantly correlated with venous invasion in patients with gastric cancer.
Lin Y; Kikuchi S; Obata Y; Yagyu K;
J Gastroenterol Hepatol; 2006 Feb; 21(2):432-7. PubMed ID: 16509870
[TBL] [Abstract][Full Text] [Related]
20. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy.
Shariat SF; Shalev M; Menesses-Diaz A; Kim IY; Kattan MW; Wheeler TM; Slawin KM
J Clin Oncol; 2001 Jun; 19(11):2856-64. PubMed ID: 11387358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
